Investor Information

Investor Information

Volpara Health Technologies (ASX: VHT) develops digital health services to enable personalised, high quality breast cancer screening based on objective measurements of breast density, compression and radiation dose.

VHT was founded in 2009 by four of the world’s leading breast imaging experts: Professor Sir John Michael Brady and Dr Ralph Highnam from the University of Oxford, Professor Nico Karssemeijer from the University of Nijmegen and Professor Martin Yaffe from the University of Toronto. VHT headquarters (R&D and engineering) were established by Dr Highnam in Wellington, New Zealand.

The first Australian users of Volpara products include Sydney Breast Clinic (NSW), Imaging Associates Radiology (Wagga Wagga, NSW), Dr Jones & Partners Medical Imaging (Adelaide, SA), Flinders Medical Centre (Adelaide, SA), Lyell McEwan Hospital (Elizabeth Vale, SA), MIA Monash Radiology (Melbourne, VIC), Imaging Associates - Mitcham Private Hospital (Melbourne, VIC) and Women’s & Breast Imaging (Perth). Volpara users in Auckland, New Zealand are the breast imaging pioneers Auckland Breast Centre and St Marks Breast Centre.

VHT Investor Newsletters

Signup for our VHT investor newsletters at the bottom of this page.

October 2017

August 2017

May 2017

December 2016 (PDF, 475 KB)

September 2016 (PDF, 2 MB)

Contact Us

Investor Relations email

investors@volparasolutions.com

Main business address

Level 7, 44 Victoria Street
Wellington 6011, New Zealand

Registered offices

Volpara Health Technologies
Level 7, 44 Victoria Street
Wellington Central, Wellington 6011, New Zealand

JFDCPA Advisers
Suite #9, Level 1, 357 Military Road
Mosman, NSW 2088, Australia